/ Print /

PHARMACY BEST PRACTICES

Report Slams 340B Drug Discount ProgramA Pacific Research Institute report revealed that the 340B program is in desperate need of reform, while 340B Health refutes damaging claims.
Three Barriers to Biosimilar AdoptionUnderstanding the key barriers to biosimilar adoption in the U.S. is the first step managed care executives can take to overcome these obstacles, according to a Trinity Parners report.
Groundbreaking gene therapies in store for hemophiliaTreatment failures can result in a spectrum of problems for patients with hemophilia. Here’s some guidance on choosing the right therapy.
Some Consumers Set to Receive Complimentary Cancer Genomic ProfilingShift represents growing understanding of value of genetic testing for cancers. Find out who is receiving the test and why.
Amazon, JPMorgan, Berkshire Hathaway collaboration puts insurers ‘on notice’Corporate giants Amazon, Berkshire Hathaway, and JPMorgan Chase, partner to shake things up in U.S. employee healthcare.
How a customized COPD care bundle is reducing readmissionsReducing readmissions for chronic obstructive pulmonary disease (COPD) is an ongoing challenge for healthcare systems. Here’s how one is successful.
How the Flu’s Severity Will Effect Healthcare SpendingThe flu epidemic is taking a toll on the U.S. healthcare system. Here's how health insurers can curtail spending on flu care.
Pfizer VP Robert Popovian Talks Value-Based ReimbursementThe impact of VBRs on outcomes, VBRs versus other healthcare reimbursement initiatives, and VBR successes and failures. Pfizer’s Robert Popovian, PharmD, weighs in.
Four pain management programs curbing the opioid epidemicFrom State-led programs to innovative pharmacist-hospital partnerships, these programs are fighting to quell the epidemic.
Expert Predictions: Generic Drug Costs, Biosimilar Impact, Policy ChangesHow are generic prices changing, how will biosimilars impact costs, and what changes out of Washington should healthcare executives watch? Economics guru Joe Fuhr weighs in.